NasdaqGM - Nasdaq Real Time Price USD
Intellia Therapeutics, Inc. (NTLA)
As of 1:50 PM EST. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 24 | 11 | 26 | 26 |
| Avg. Estimate | -1.33 | -1.38 | -5.28 | -5.47 |
| Low Estimate | -1.61 | -1.52 | -6.42 | -6.78 |
| High Estimate | -0.88 | -1.14 | -4.02 | -4.14 |
| Year Ago EPS | -1.46 | -1.12 | -5.42 | -5.28 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 24 | 12 | 29 | 29 |
| Avg. Estimate | 8.9M | 9.34M | 52.87M | 52.19M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 34.8M | 16.3M | 79.8M | 210M |
| Year Ago Sales | -1.92M | 28.93M | 36.27M | 52.87M |
| Sales Growth (year/est) | 564.50% | -67.72% | 45.76% | -1.29% |
Earnings History
| CURRENCY IN USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -1.44 | -1.36 | -1.2 | -1.37 |
| EPS Actual | -1.46 | -1.12 | -1.52 | -1.34 |
| Difference | -0.02 | 0.24 | -0.32 | 0.03 |
| Surprise % | -1.71% | 17.66% | -27.02% | 2.13% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.33 | -1.38 | -5.28 | -5.47 |
| 7 Days Ago | -1.34 | -1.37 | -5.15 | -5.44 |
| 30 Days Ago | -1.4 | -1.41 | -5.37 | -5.53 |
| 60 Days Ago | -1.4 | -1.41 | -5.39 | -5.58 |
| 90 Days Ago | -1.4 | -1.41 | -5.4 | -5.6 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 15 | 6 | 15 | 12 |
| Up Last 30 Days | 14 | 5 | 15 | 11 |
| Down Last 7 Days | 5 | -- | 6 | 10 |
| Down Last 30 Days | 6 | 1 | 7 | 12 |
Growth Estimates
| CURRENCY IN USD | NTLA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 9.21% | -- | -- | 5.00% |
| Next Qtr. | -23.13% | -- | -- | 12.00% |
| Current Year | 2.60% | -- | -- | 2.10% |
| Next Year | -3.63% | -- | -- | 12.20% |
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 11/19/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 11/18/2024 |
| Reiterates | Wedbush: Neutral to Neutral | 11/18/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/18/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 11/11/2024 |
| Maintains | Barclays: Overweight to Overweight | 11/8/2024 |
Related Tickers
CRSP CRISPR Therapeutics AG
46.33
-1.97%
BEAM Beam Therapeutics Inc.
24.12
-1.51%
EDIT Editas Medicine, Inc.
2.3750
-1.45%
RXRX Recursion Pharmaceuticals, Inc.
5.81
-3.74%
VKTX Viking Therapeutics, Inc.
53.57
+3.96%
IOVA Iovance Biotherapeutics, Inc.
8.27
+1.54%
VERV Verve Therapeutics, Inc.
4.6550
+2.31%
INCY Incyte Corporation
69.86
-1.67%
FATE Fate Therapeutics, Inc.
2.0450
-7.88%
APLS Apellis Pharmaceuticals, Inc.
27.39
-0.36%